BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 33599007)

  • 21. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
    Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
    J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. H3 K27M-mutant gliomas in adults vs. children share similar histological features and adverse prognosis.
    Kleinschmidt-DeMasters BK; Mulcahy Levy JM
    Clin Neuropathol; 2018; 37 (2018)(2):53-63. PubMed ID: 29393845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diffuse midline glioma of the cervical spinal cord with H3 K27M genotype phenotypically mimicking anaplastic ganglioglioma: a case report and review of the literature.
    Kraus TFJ; Machegger L; Pöppe J; Zellinger B; Dovjak E; Schlicker HU; Schwartz C; Ladisich B; Spendel M; Kral M; Reinhardt A; Winkler PA; Sotlar K
    Brain Tumor Pathol; 2020 Jul; 37(3):89-94. PubMed ID: 32451719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diffuse Midline Gliomas With Histone H3 K27M Mutation in Adults and Children: A Retrospective Series of 164 Cases.
    Zheng L; Gong J; Yu T; Zou Y; Zhang M; Nie L; Chen X; Yue Q; Liu Y; Mao Q; Zhou Q; Chen N
    Am J Surg Pathol; 2022 Jun; 46(6):863-871. PubMed ID: 35416795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.
    Neth BJ; Balakrishnan SN; Carabenciov ID; Uhm JH; Daniels DJ; Kizilbash SH; Ruff MW
    J Neurooncol; 2022 Mar; 157(1):91-100. PubMed ID: 35076860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spinal Cord Diffuse Midline Gliomas With H3 K27m-Mutant: Clinicopathological Features and Prognosis.
    Wang YZ; Zhang YW; Liu WH; Chai RC; Cao R; Wang B; An SY; Jiang WJ; Xu YL; Yang J; Jia WQ
    Neurosurgery; 2021 Jul; 89(2):300-307. PubMed ID: 34015818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. H3F3A mutant allele specific imbalance in an aggressive subtype of diffuse midline glioma, H3 K27M-mutant.
    Maeda S; Ohka F; Okuno Y; Aoki K; Motomura K; Takeuchi K; Kusakari H; Yanagisawa N; Sato S; Yamaguchi J; Tanahashi K; Hirano M; Kato A; Shimizu H; Kitano Y; Yamazaki S; Yamashita S; Takeshima H; Shinjo K; Kondo Y; Wakabayashi T; Natsume A
    Acta Neuropathol Commun; 2020 Feb; 8(1):8. PubMed ID: 32019606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adult diffuse midline gliomas: Clinical, radiological, and genetic characteristics.
    Dono A; Takayasu T; Ballester LY; Esquenazi Y
    J Clin Neurosci; 2020 Dec; 82(Pt A):1-8. PubMed ID: 33317715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical, Pathological, and Molecular Characteristics of Diffuse Spinal Cord Gliomas.
    Garcia MR; Feng Y; Vasudevaraja V; Galbraith K; Serrano J; Thomas C; Radmanesh A; Hidalgo ET; Harter DH; Allen JC; Gardner SL; Osorio DS; William CM; Zagzag D; Boué DR; Snuderl M
    J Neuropathol Exp Neurol; 2022 Oct; 81(11):865-872. PubMed ID: 35997552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.
    Khuong-Quang DA; Buczkowicz P; Rakopoulos P; Liu XY; Fontebasso AM; Bouffet E; Bartels U; Albrecht S; Schwartzentruber J; Letourneau L; Bourgey M; Bourque G; Montpetit A; Bourret G; Lepage P; Fleming A; Lichter P; Kool M; von Deimling A; Sturm D; Korshunov A; Faury D; Jones DT; Majewski J; Pfister SM; Jabado N; Hawkins C
    Acta Neuropathol; 2012 Sep; 124(3):439-47. PubMed ID: 22661320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Magnetic Resonance Imaging Characteristics of Molecular Subgroups in Pediatric H3 K27M Mutant Diffuse Midline Glioma.
    Hohm A; Karremann M; Gielen GH; Pietsch T; Warmuth-Metz M; Vandergrift LA; Bison B; Stock A; Hoffmann M; Pham M; Kramm CM; Nowak J
    Clin Neuroradiol; 2022 Mar; 32(1):249-258. PubMed ID: 34919158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An adult case of diffuse midline glioma with H3 K27M mutation.
    Tu JH; Piao YS; Lu DH; Wang LM; Liu L; Bai DY; Han HW; Lin YK; Zhong S
    Neuropathology; 2020 Dec; 40(6):627-631. PubMed ID: 32954563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
    Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
    Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
    [No Abstract]   [Full Text] [Related]  

  • 34. Spinal cord high-grade infiltrating gliomas in adults: clinico-pathological and molecular evaluation.
    Alvi MA; Ida CM; Paolini MA; Kerezoudis P; Meyer J; Barr Fritcher EG; Goncalves S; Meyer FB; Bydon M; Raghunathan A
    Mod Pathol; 2019 Sep; 32(9):1236-1243. PubMed ID: 31028365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical, imaging, and molecular analysis of pediatric pontine tumors lacking characteristic imaging features of DIPG.
    Chiang J; Diaz AK; Makepeace L; Li X; Han Y; Li Y; Klimo P; Boop FA; Baker SJ; Gajjar A; Merchant TE; Ellison DW; Broniscer A; Patay Z; Tinkle CL
    Acta Neuropathol Commun; 2020 Apr; 8(1):57. PubMed ID: 32326973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diffuse hemispheric glioma with H3 p.K28M (K27M) mutation: Unusual non-midline presentation of diffuse midline glioma, H3 K27M-altered?
    Donev K; Sundararajan V; Johnson D; Balan J; Chambers M; Paulson VA; Scherpelz KP; Abdullaev Z; Quezado M; Cimino PJ; Pratt D; Valerio E; Alves de Castro JV; Carraro DM; Torrezan GT; Wolff BM; Kulikowski LD; Costa FD; Aldape K; Ida CM
    J Neuropathol Exp Neurol; 2024 Apr; 83(5):357-364. PubMed ID: 38447592
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
    Odia Y; Hall MD; Cloughesy TF; Wen PY; Arrillaga-Romany I; Daghistani D; Mehta MP; Tarapore RS; Ramage SC; Allen JE
    Neuro Oncol; 2024 May; 26(Supplement_2):S165-S172. PubMed ID: 38386699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicoradiological characteristics of primary spinal cord H3 K27M-mutant diffuse midline glioma.
    Cheng L; Wang L; Yao Q; Ma L; Duan W; Guan J; Zhang C; Wang K; Liu Z; Wang X; Wang Z; Wu H; Chen Z; Jian F
    J Neurosurg Spine; 2022 Feb; 36(2):303-314. PubMed ID: 34560639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Rare High-Grade Glioma with a Histone H3 K27M Mutation in the Hypothalamus of an Adult Patient.
    He P; Chen W; Qiu XX; Xi YB; Guan H; Xia J
    World Neurosurg; 2019 Aug; 128():527-531. PubMed ID: 31048046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tectal Low-Grade Glioma with H3 K27M Mutation.
    Sumi K; Shijo K; Igarashi T; Yamamuro S; Sasano M; Oshima H; Ishige T; Honma T; Yagasaki H; Yoshino A
    World Neurosurg; 2020 Sep; 141():91-100. PubMed ID: 32505657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.